tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingivitis D005891 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Hemophilia B D002836 3 associated lipids
Pouchitis D019449 3 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Pemphigus D010392 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Pterygium D011625 3 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Headache D006261 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Hallucinations D006212 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Prurigo D011536 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Viremia D014766 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gout D006073 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Guy S et al. Immunosuppression conversion for relief of side effects. 1994 Transplant. Proc. pmid:7527956
Knoop C et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. 1994 Transplant. Proc. pmid:7527957
Yashima J et al. Successful conversion from tacrolimus to cyclosporine after kidney transplantation. 2000 Transplant. Proc. pmid:11119895
Gibbs JF et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. 1993 Transplant. Proc. pmid:7679823
Nomoto S et al. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. 1994 Transplant. Proc. pmid:7513477
Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. 1993 Transplant. Proc. pmid:7679824
Kato H et al. Spontaneous proliferation of peripheral blood mononuclear cells as an indicator for insufficient plasma levels of FK 506 in the early phase after liver transplantation. 1994 Transplant. Proc. pmid:7513481
Siekierka JJ et al. Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. 1991 Transplant. Proc. pmid:1721256
Morris RE In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. 1991 Transplant. Proc. pmid:1721257
Satomura K et al. Pharmacokinetics of FK 506 in living-related liver transplantation. 1996 Transplant. Proc. pmid:8623209
Loss M et al. Glucose and lipid metabolism in liver transplant patients under long-term tacrolimus (FK 506) monotherapy. 1996 Transplant. Proc. pmid:8623210
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Machado PG et al. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation. 2002 Transplant. Proc. pmid:11959207
Zervos XA et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplant. Proc. pmid:9636568
Videla CO Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy. 2009 Jul-Aug Transplant. Proc. pmid:19715995
Melo MJ et al. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study. 2015 Transplant. Proc. pmid:26036484
Santos T et al. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients. 2015 Transplant. Proc. pmid:26036483
Viganó J et al. Incidence of graft rejection in small bowel transplanted pigs after immunosuppression withdrawal. 2006 Jul-Aug Transplant. Proc. pmid:16908291
Higuchi K et al. FK506 induces the atrophy of enteric ganglia in small bowel transplantation, which can be prevented by the neuropeptide bombesin. 2006 Jul-Aug Transplant. Proc. pmid:16908293
Koyamada N et al. Strategy for chronic rejection in recipient of living-related liver transplantation. 2000 Transplant. Proc. pmid:11120102
Kaplinsky E et al. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients. 2012 Transplant. Proc. pmid:23146455
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Harihara Y et al. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. 2000 Transplant. Proc. pmid:11120116
Yilmaz A et al. Severe angioedema caused by banana allergy under tacrolimus immunosuppression. 2005 Transplant. Proc. pmid:16387091
Lai WJ et al. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? 2004 Transplant. Proc. pmid:15518744
Kohnle M et al. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. 1999 Transplant. Proc. pmid:10576043
Barten MJ et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. 2005 Transplant. Proc. pmid:16387162
Chueh SC et al. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. 2004 Transplant. Proc. pmid:15518745
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Ueno M et al. Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. 1992 Transplant. Proc. pmid:1373546
van Hooff JP et al. Tacrolimus and glucose metabolism. 1999 Transplant. Proc. pmid:10576044
D'Silva M et al. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623467
Meçule A et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. 2010 Transplant. Proc. pmid:20534290
Burke GW et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. 1998 Transplant. Proc. pmid:9636627
Gruessner RW Antibody induction therapy in pancreas transplantation. 1998 Transplant. Proc. pmid:9636632
Bakar F et al. Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus. 2009 Transplant. Proc. pmid:19545695
Marcén R et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. 2010 Transplant. Proc. pmid:20970609
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Platz KP et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. 1997 Transplant. Proc. pmid:9365598
Villamil F et al. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. 2006 Transplant. Proc. pmid:17112875
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Demetris AJ et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. 1993 Transplant. Proc. pmid:7505503
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Todo S et al. Intestinal transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7518136
Mucha K et al. 36-month follow-up of 75 renal allograft recipients treated with steroids, tacrolimus, and azathioprine or mycophenolate mofetil. 2003 Transplant. Proc. pmid:14529880
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Ushigome H et al. Two cases of tacrolimus-induced alopecia following kidney transplantation. 1999 Transplant. Proc. pmid:10578326
Woodle ES et al. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. 1993 Transplant. Proc. pmid:7682360
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Li J et al. Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. 2008 Transplant. Proc. pmid:18589137
Yang YJ et al. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. 2008 Transplant. Proc. pmid:18589147
Shibutani S et al. FK 506 abrogates induction of regulatory cells after intratracheal delivery of alloantigen. 2002 Transplant. Proc. pmid:12176432
Signorell J et al. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. 2010 Transplant. Proc. pmid:21094874
Hayes D et al. Aerosolized tacrolimus: a case report in a lung transplant recipient. 2010 Transplant. Proc. pmid:21094875
Bouchta NB et al. Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation. 2005 Transplant. Proc. pmid:15919485
Kumano K et al. Role of endothelin in FK 506-induced renal hypoperfusion in rats. 1995 Transplant. Proc. pmid:7533423
Green M et al. Infectious complications of pediatric liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721352
Altaca G et al. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival. 2002 Transplant. Proc. pmid:12270320
Torre-Cisneros J et al. The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721353
Tanabe K et al. Outcome of kidney transplantation from non-heart-beating donors followed by tacrolimus immunosuppression in japan. 2002 Transplant. Proc. pmid:12176493
Squifflet JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. 2002 Transplant. Proc. pmid:12176495
Ko WJ et al. Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. 1998 Transplant. Proc. pmid:9838474
Cho JH et al. Chronic rejection in pediatric liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123078
Spada M et al. Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. 1996 Transplant. Proc. pmid:8907997
Hara Y et al. Heterotopic rat heart transplantation to the iliac vessels. 1994 Transplant. Proc. pmid:7520632
Takayama K et al. Nonmuscle myosin heavy chain and nuclear factor-kappa B expression in pig-to-primate xenotransplanted hearts. 2000 Transplant. Proc. pmid:10936372
McCauley J et al. Changes in renal function after liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721385
Boots JM et al. Risk of adrenal insufficiency with steroid maintenance therapy in renal transplantation. 2002 Transplant. Proc. pmid:12176541
Lee S et al. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. 2010 Transplant. Proc. pmid:20430174
Klupp J et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083497
Kim JM et al. Preemptive therapy in adult liver transplant recipients in CMV-endemic area. 2010 Transplant. Proc. pmid:20430182
Yang HC et al. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. 1999 Feb-Mar Transplant. Proc. pmid:10083501
Alessiani M et al. Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression. 1997 Feb-Mar Transplant. Proc. pmid:9123483
Galvao FH et al. Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. 1997 Feb-Mar Transplant. Proc. pmid:9123488
Kimura O et al. Influence of bombesin on the intestinal mucosal immunologic response under immunosuppression. 2000 Transplant. Proc. pmid:10995942
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Fukuzaki T et al. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. 1991 Transplant. Proc. pmid:1721415
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Watanabe K et al. Immunosuppressive effect of bactobolamine in rat liver allotransplantation. 1996 Transplant. Proc. pmid:8658697
Yamanaka K et al. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. 2016 Transplant. Proc. pmid:27234735
Dette K et al. Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous [correction of simultaneus] pancreas-kidney transplantation: analysis of early outcome. 2002 Transplant. Proc. pmid:12176624
Navaneethan SD et al. Tacrolimus-associated hypomagnesemia in renal transplant recipients. 2006 Transplant. Proc. pmid:16797291
Zaltzman J et al. Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267183
Burrows L et al. Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients. 1998 Transplant. Proc. pmid:9723378
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Viebahn R et al. Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. 1993 Transplant. Proc. pmid:7689278
Wang CH et al. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. 2004 Transplant. Proc. pmid:15561257
Heffron TG et al. Daclizumab induction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267408
Rabkin JM et al. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267411
Uber PA et al. Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267428
Nakai T et al. Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. 1999 Transplant. Proc. pmid:10500761
Krüger B et al. Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. 1998 Transplant. Proc. pmid:9636399
McAlister VC Liposomal tacrolimus: drug migration within blood compartments. 1998 Transplant. Proc. pmid:9636404
Zhang J et al. Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients. 2010 Transplant. Proc. pmid:21094797
Gotsman I et al. Effect of peripheral immune tolerance on liver-associated lymphocytes expressing NK1.1. 2000 Transplant. Proc. pmid:10856569
Soh KS et al. Simultaneous liver and kidney transplantation from different living donors. 2012 Transplant. Proc. pmid:22410057
Blume C et al. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750357
Busque S et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. 1998 Transplant. Proc. pmid:9636507